Diversified Trust Co Acquires New Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Diversified Trust Co acquired a new stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 17,502 shares of the company's stock, valued at approximately $1,433,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Riverview Trust Co bought a new position in Vaxcyte in the 3rd quarter valued at about $27,000. Blue Trust Inc. grew its position in shares of Vaxcyte by 33.5% in the third quarter. Blue Trust Inc. now owns 371 shares of the company's stock valued at $42,000 after purchasing an additional 93 shares during the last quarter. Meeder Asset Management Inc. increased its stake in shares of Vaxcyte by 1,007.9% during the third quarter. Meeder Asset Management Inc. now owns 698 shares of the company's stock worth $80,000 after purchasing an additional 635 shares during the period. Nomura Asset Management Co. Ltd. acquired a new stake in Vaxcyte during the 3rd quarter worth approximately $92,000. Finally, Quest Partners LLC bought a new stake in Vaxcyte in the 2nd quarter valued at $70,000. 96.78% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, COO Jim Wassil sold 8,000 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $83.66, for a total value of $669,280.00. Following the completion of the transaction, the chief operating officer now owns 205,695 shares of the company's stock, valued at approximately $17,208,443.70. This represents a 3.74 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Grant Pickering sold 15,000 shares of Vaxcyte stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $106.82, for a total transaction of $1,602,300.00. Following the sale, the chief executive officer now directly owns 435,219 shares in the company, valued at $46,490,093.58. This trade represents a 3.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 113,732 shares of company stock worth $11,730,787 over the last three months. Insiders own 3.10% of the company's stock.

Analysts Set New Price Targets

PCVX has been the topic of several recent research reports. Cantor Fitzgerald reiterated an "overweight" rating on shares of Vaxcyte in a research report on Wednesday, November 6th. The Goldman Sachs Group initiated coverage on shares of Vaxcyte in a research note on Friday, December 20th. They issued a "buy" rating and a $135.00 price target on the stock. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $140.00 price objective on shares of Vaxcyte in a research note on Wednesday, November 6th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $145.71.

Vaxcyte Price Performance

PCVX traded down $6.23 on Thursday, hitting $81.06. 1,266,762 shares of the stock were exchanged, compared to its average volume of 925,932. The firm has a market capitalization of $10.10 billion, a price-to-earnings ratio of -17.62 and a beta of 0.98. Vaxcyte, Inc. has a 12 month low of $58.10 and a 12 month high of $121.06. The business has a 50-day moving average of $90.72 and a two-hundred day moving average of $93.23.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, topping analysts' consensus estimates of ($1.10) by $0.27. During the same quarter in the prior year, the company posted ($0.91) EPS. Equities research analysts expect that Vaxcyte, Inc. will post -4.14 earnings per share for the current fiscal year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.